The effect of intravitreal adalimumab injection on pseudophakic macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016100430130N1

Enrollment

Registered

2016-12-03

Start date

2016-10-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudophakic macular edema. Other specified retinal disorders

Interventions

intravitreal adalimumab injection.

Treatment - Drugs

intravitreal adalimumab injection

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with pseudophakic macular edema and PCIOL in bag who have received prior treatment (topical NSAIDs or topical corticosteroids). Exclusion criteria: patients with macular edema due to causes other than pseudophakia(diabetes, uveitis, retinitis pigmentosa); complicated surgery (vitrous loss); PCIOL in sulcus and ACIOL.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Visual acuity. Timepoint: Before injection, 1 week and 1 month after injection. Method of measurement: Snellen chart.	—

Secondary

Measure	Time frame
Central macular thickness. Timepoint: Before injection, 1 week and 1 month after injection. Method of measurement: OCT.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Mohsen Farvardin

Shiraz University of Medical Sciences

farvardm@sums.ac.ir+98 71 3230 5410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 26, 2026